(UroToday.com) The AUA’s Drug Development in NMIBC From Scientific, Regulatory, Clinician, and Patient Perspectives virtual meeting session on clinical dilemmas in the management of non-muscle-invasive bladder cancer (NMIBC) included a discussion of clinical trial design considerations for intermediate-risk non-muscle-invasive bladder cancer (NMIBC) by Dr. Trinity Bivalacqua.
Ashish Kamat: Hello, and welcome to UroToday’s Bladder Cancer Center of Excellence, your one-stop destination for the latest developments in the field of bladder cancer. And along these lines, it’s my pleasure to welcome today, Professor Anne Schuckman, who is Assistant Professor and Director of Urologic Oncology at USC/Keck Department of Urology in Los Angeles, […]
Alicia Morgans: Hi, my name is Alicia Morgans, and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University. I’m so excited to talk today with Dr. Eleni Efstathiou, who is an Associate Professor of Medicine and a GU Medical Oncologist at MD Anderson. Thank you so much for being here with […]
Petros Grivas: Hello, I’m Dr. Petros Grivas. I’m a Medical Oncologist at the Seattle Cancer Care Alliance. I’m an Associate Professor of University of Washington, and Fred Hutchinson Cancer Research Center. I’m very excited today to host Dr. Ali Khaki, who’s an Assistant Professor at Stanford University. He was a MNT for our team here […]
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, there […]
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, there […]
(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, there […]
High-risk ureteral tumors represent an understudied subset of upper tract urothelial carcinoma, whose surgical management can range from a radical nephroureterectomy (NU) to segmental ureterectomy (SU).
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. In this phase 3, randomized, open-label trial, we randomly assigned adults with previously untreated clear-cell, advanced renal-cell carcinoma to receive either nivolumab (240 mg every 2 weeks) plus cabozantinib […]
Using multiparametric MRI data and the pathologic data from radical prostatectomy specimens, we simulated the treatment planning of dose-escalated high-dose-rate brachytherapy (HDR-BT) to the Multiparametric MRI dominant intraprostatic lesion (mpMRI-DIL) to compare the dose potentially delivered to the pathologically confirmed locations of the high-grade component of the cancer.
